NCT02296112: A reported trial by Vanderbilt-Ingram Cancer Center
This trial has reported on time, in line with the regulations.
Full data
Full entry on ClinicalTrials.gov | NCT02296112 |
---|---|
Title | A Phase II Open-Label, Two-Arm Study of the MEK Inhibitor, Trametinib, to Investigate the Safety and Anti-Cancer Activity in Subjects With Melanoma With BRAF Non-V600 Mutations |
Results Status | Reported |
ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
Start date | Jan. 31, 2015 |
Completion date | Aug. 31, 2018 |
Required reporting date | Aug. 31, 2019, midnight |
Actual reporting date | July 15, 2019 |
Date last checked at ClinicalTrials.gov | Aug. 26, 2025 |
Days late | None |